Clinical Cell Culture Limited Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	38
ISBN Number	not applicable
Product Code	GMD04636

Price

£490.00
approximately: $749 | €546

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a Clinical Cell Culture Limited's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
3 Business Description
- 3.1 Business Overview
- 3.2 Major Products and Services
  - 3.2.1 Overview
4 History
5 Competitors
6 Key Employees
7 Key Employee Biographies
8 Company Statement
9 Locations And Subsidiaries
- 9.1 Head Office
- 9.2 Other Locations & Subsidiaries
10 Recent Developments
- 10.1 Financial Announcements
  - 10.1.1 Aug 31, 2007: C3 Declares Fiscal 2007 Results
  - 10.1.2 Feb 27, 2007: C3 Declares H1 2007 Results
  - 10.1.3 Sep 07, 2006: C3 Declares Fiscal 2006 Results
- 10.2 Corporate Communications
  - 10.2.1 Feb 15, 2008: C3 Directors Resigns
- 10.3 Product News
  - 10.3.1 Aug 07, 2008: Avita Signs Greek Distribution Deal
  - 10.3.2 Jul 21, 2008: Chinese SFDA Approves Helicon Group's ReCell Concept And Kit
  - 10.3.3 Jul 03, 2008: Avita ReCell Product Approved In China
  - 10.3.4 Dec 15, 2006: Recell Approved In Brazil And Turkey
  - 10.3.5 Nov 27, 2006: Update On US Regulatory Approval For Recell
  - 10.3.6 Nov 14, 2006: Recell Clinical Update
  - 10.3.7 Nov 08, 2006: Cellspray Approved In Greece
  - 10.3.8 Sep 28, 2006: Clinical Cell Culture Announces CSL Supply Agreement
  - 10.3.9 Jun 27, 2006: Recell Approved In Canada
  - 10.3.10 May 25, 2006: TGA Approves Recell
  - 10.3.11 Apr 03, 2006: TGA Recommends Recell For Approval
  - 10.3.12 Jan 16, 2006: Regulatory Update On Recell FDA And TGA
- 10.4 Product Approvals
  - 10.4.1 Jul 21, 2008: Chinese SFDA Approves Helicon Group's ReCell Concept And Kit
  - 10.4.2 Jul 03, 2008: Avita ReCell Product Approved In China
  - 10.4.3 Dec 15, 2006: Recell Approved In Brazil And Turkey
  - 10.4.4 Nov 08, 2006: Cellspray Approved In Greece
  - 10.4.5 Jun 27, 2006: Recell Approved In Canada
  - 10.4.6 May 25, 2006: TGA Approves Recell
- 10.5 Clinical Trials
  - 10.5.1 Nov 14, 2006: Recell Clinical Update
- 10.6 Other Significant Developments
  - 10.6.1 May 06, 2008: C3 Proposes Name Change
11 Clinical Cell Culture Limited Pipeline Products
- 11.1 Clinical Cell Culture Limited Product Pipeline Analysis
  - 11.1.1 Clinical Cell Culture Limited Pipeline Products By Equipment Type
  - 11.1.2 Clinical Cell Culture Limited Pipeline Products By Development Stage
  - 11.1.3 Clinical Cell Culture Limited Pipeline Products By Therapy Area
  - 11.1.4 Clinical Cell Culture Limited Pipeline Products By News Summary
- 11.2 Cell Delivery Device (CDD)
  - 11.2.1 Product Description
  - 11.2.2 Product Status
- 11.3 ReCell
  - 11.3.1 Product Description
  - 11.3.2 Product Status
  - 11.3.3 Product Milestone
- 11.4 CellSpray
  - 11.4.1 Product Description
  - 11.4.2 Product Status
  - 11.4.3 Product Milestone
- 11.5 CellSpray XP
  - 11.5.1 Product Description
  - 11.5.2 Product Status
12 Appendix
- 12.1 Methodology
  - 12.1.1 Coverage
  - 12.1.2 Secondary Research
  - 12.1.3 Primary Research
  - 12.1.4 Expert Panel Validation
- 12.2 Contact Us
- 12.3 About Global Markets Direct
- 12.4 Disclaimer
1 List of Tables
- Table 1: Clinical Cell Culture Limited,Key Facts
- Table 2: Clinical Cell Culture Limited, Key Employees,
- Table 3: Clinical Cell Culture Limited, Subsidiaries
- Table 4: Clinical Cell Culture Limited Pipeline Products by Equipment Type
- Table 5: Clinical Cell Culture Limited Pipeline Products By Development Stage
- Table 6: Clinical Cell Culture Limited Pipeline Products By Therapy Area
- Table 7: Clinical Cell Culture Limited Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: Clinical Cell Culture Limited Pipeline Products By Development Stage
- Figure 2: Clinical Cell Culture Limited Pipeline Products By News Summary
- Figure 3: Global Markets Direct Methodology